Castle Biosciences, Inc.

SciBase Rights Issue Fully Covered as Bergs Securities Confirms SEK 24.2M Guarantee

Stockholm – September 25, 2026 -- SciBase Holding AB's SEK 57.5 million rights issue is now fully covered after Bergs Securities AB confirmed a binding guarantee commitment of approximately SEK 24.2 million, equal to 42 percent of the offering.

Guarantee commitment converts letter of intent into binding coverage

Bergs Securities fulfilled on September 25, 2026, a guarantee intention it first announced on September 3, 2026, by delivering a formal guarantee confirmation to SciBase. The firm has backed the commitment with sub-guarantee agreements from a consortium of investors covering the full guaranteed amount.

Study: 55% of AD Patients Switch Systemic Therapy Over Efficacy Gaps

Friendswood, Texas – September 25, 2026 -- More than half of atopic dermatitis (AD) patients who used targeted systemic therapies modified treatment because the drugs failed to work, according to a new study published in Dermatology and Therapy by Castle Biosciences, Inc. (Nasdaq: CSTL).

Study finds 55% of systemic therapy users switched due to lack of efficacy

The research surveyed 43 AD patients and caregivers who completed a 32-question assessment at the 2024 National Eczema Association Eczema Expo. Among respondents who had used targeted systemic therapies, 55% reported modifying treatment because of insufficient results. Inadequate skin clearance and persistent itching were cited as the most frequent reasons for switching drugs or adding topical treatments.